JP7535514B2 - Ｄｐｅｐ－１結合剤および使用の方法 - Google Patents

Ｄｐｅｐ－１結合剤および使用の方法 Download PDF

Info

Publication number
JP7535514B2
JP7535514B2 JP2021530885A JP2021530885A JP7535514B2 JP 7535514 B2 JP7535514 B2 JP 7535514B2 JP 2021530885 A JP2021530885 A JP 2021530885A JP 2021530885 A JP2021530885 A JP 2021530885A JP 7535514 B2 JP7535514 B2 JP 7535514B2
Authority
JP
Japan
Prior art keywords
peptide
dpep
binding
cells
lsalt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509258A (ja
JPWO2020109864A5 (https=
JP2022509258A5 (https=
Inventor
スティーブン マーク ロビンズ，
ドナ ロレイン センガー，
ダニエル アブラハム ムルベ，
サウラブ ロイ チョウドリー，
ジェニファー ジョイ ラーン，
アーサー ウィング ジィー ラウ，
ジャスティン マクドナルド，
リアン バーベス，
ポール クベス，
Original Assignee
アーチ バイオパートナーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーチ バイオパートナーズ， インコーポレイテッド filed Critical アーチ バイオパートナーズ， インコーポレイテッド
Publication of JP2022509258A publication Critical patent/JP2022509258A/ja
Publication of JPWO2020109864A5 publication Critical patent/JPWO2020109864A5/ja
Publication of JP2022509258A5 publication Critical patent/JP2022509258A5/ja
Priority to JP2024007364A priority Critical patent/JP2024028553A/ja
Application granted granted Critical
Publication of JP7535514B2 publication Critical patent/JP7535514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021530885A 2018-11-30 2019-12-02 Ｄｐｅｐ－１結合剤および使用の方法 Active JP7535514B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024007364A JP2024028553A (ja) 2018-11-30 2024-01-22 Ｄｐｅｐ－１結合剤および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773733P 2018-11-30 2018-11-30
US62/773,733 2018-11-30
PCT/IB2019/001289 WO2020109864A1 (en) 2018-11-30 2019-12-02 Dpep-1 binding agents and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024007364A Division JP2024028553A (ja) 2018-11-30 2024-01-22 Ｄｐｅｐ－１結合剤および使用の方法

Publications (4)

Publication Number Publication Date
JP2022509258A JP2022509258A (ja) 2022-01-20
JPWO2020109864A5 JPWO2020109864A5 (https=) 2022-10-05
JP2022509258A5 JP2022509258A5 (https=) 2022-10-05
JP7535514B2 true JP7535514B2 (ja) 2024-08-16

Family

ID=70853301

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530885A Active JP7535514B2 (ja) 2018-11-30 2019-12-02 Ｄｐｅｐ－１結合剤および使用の方法
JP2024007364A Pending JP2024028553A (ja) 2018-11-30 2024-01-22 Ｄｐｅｐ－１結合剤および使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024007364A Pending JP2024028553A (ja) 2018-11-30 2024-01-22 Ｄｐｅｐ－１結合剤および使用の方法

Country Status (7)

Country Link
US (3) US11286278B2 (https=)
EP (1) EP3887390A4 (https=)
JP (2) JP7535514B2 (https=)
AU (1) AU2019386379B2 (https=)
CA (1) CA3121300A1 (https=)
IL (1) IL283231B1 (https=)
WO (1) WO2020109864A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合剤および使用の方法
EP4320167A4 (en) * 2021-04-08 2025-08-06 Nat Res Council Canada DPEP-1 BINDING AGENTS AND METHODS OF USE THEREOF
EP4574146A1 (en) 2023-12-18 2025-06-25 Telara Pharma S.L. Dhp-i inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030195163A1 (en) 2001-07-11 2003-10-16 Shujian Wu Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
JP2017508734A (ja) 2014-02-13 2017-03-30 アーチ キャンサー セラピューティクス，インク 白血球動員をブロックするペプチドおよび使用方法
JP2018528263A (ja) 2015-08-11 2018-09-27 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ−１結合組成物および使用の方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081751A2 (en) * 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
EP2561359A1 (en) * 2010-04-20 2013-02-27 Addex Pharma SA Chimeric polypeptides useful in proximal and dynamic high-throughput screening methods
WO2012112420A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Treatments using psma ligand endopeptidases
EP3519443A4 (en) * 2016-09-30 2020-06-10 Baylor College of Medicine CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
JP2019529499A (ja) * 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 組織指向性発現を用いた抗体ベースの遺伝子治療
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合剤および使用の方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030195163A1 (en) 2001-07-11 2003-10-16 Shujian Wu Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
JP2017508734A (ja) 2014-02-13 2017-03-30 アーチ キャンサー セラピューティクス，インク 白血球動員をブロックするペプチドおよび使用方法
JP2018528263A (ja) 2015-08-11 2018-09-27 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ−１結合組成物および使用の方法

Also Published As

Publication number Publication date
EP3887390A4 (en) 2022-11-23
JP2024028553A (ja) 2024-03-04
AU2019386379B2 (en) 2025-05-22
US20220251140A1 (en) 2022-08-11
CA3121300A1 (en) 2020-06-04
IL283231B1 (en) 2026-03-01
AU2019386379A1 (en) 2021-07-15
JP2022509258A (ja) 2022-01-20
US20200223888A1 (en) 2020-07-16
IL283231A (en) 2021-07-29
US11286278B2 (en) 2022-03-29
EP3887390A1 (en) 2021-10-06
US20250333443A1 (en) 2025-10-30
WO2020109864A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
US20250333443A1 (en) Dpep-1 binding agents and methods of use
US12569538B2 (en) DPEP-1 binding compositions and methods of use
US20060172938A1 (en) Peptide inhibitors against seprase
US11083773B2 (en) Peptides that block leukocyte recruitment and methods of use
CN103214555B (zh) 介导应激反应的肽抑制剂
JP7785292B2 (ja) 血管新生および血管機能を阻害するオリゴペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240731

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240805

R150 Certificate of patent or registration of utility model

Ref document number: 7535514

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150